Q2 2021

Filed Aug 13, 2021 · 10-Q · 44 days after period end · 0001477932-21-005443

Q2 2021 · 10-Q

Revenue

$15.72K

−53.4% vs Q2 2020

Net Income

-$1.06M

N/M vs Q2 2020

EPS Diluted

-$0.16

N/M vs Q2 2020

Operating Income-$963,406N/M

Operating Cash Flow

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	$15.72K	$33.70K	$65.98K	$98.67K
Net Income	-$1.06M	-$738.48K	-$2.04M	-$1.22M
EPS Diluted	-$0.16	-$0.14	-$0.67	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR